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Abstract
Indoleamine 2,3-dioxygenase (IDO) is one of the initial and rate-
limiting enzymes involved in the catabolism of the essential
amino acid tryptophan. In cultured cells, the induction of IDO
leads to depletion of tryptophan and tryptophan starvation.
Recent studies suggest that modulation of tryptophan
concentration via IDO plays a fundamental role in innate immune
responses. Induction of IDO by interferon-γ in macrophages and
dendritic cells results in tryptophan depletion and suppresses
the immune-mediated activation of fibroblasts and T, B, and
natural killer cells. To assess the role of IDO in collagen-induced
arthritis (CIA), a model of rheumatoid arthritis characterized by a
primarily Th1-like immune response, activity of IDO was inhibited
by 1-methyl-tryptophan (1-MT) in vivo. The results showed
significantly increased incidence and severity of CIA in mice
treated with 1-MT. Activity of IDO, as determined by measuring
the levels of kynurenine/tryptophan ratio in the sera, was
increased in the acute phase of arthritis and was higher in
collagen-immunized mice that did not develop arthritis.
Treatment with 1-MT resulted in an enhanced cellular and
humoral immune response and a more dominant polarization to
Th1 in mice with arthritis compared with vehicle-treated arthritic
mice. The results demonstrated that development of CIA was
associated with increased IDO activity and enhanced
tryptophan catabolism in mice. Blocking IDO with 1-MT
aggravated the severity of arthritis and enhanced the immune
responses. These findings suggest that IDO may play an
important and novel role in the negative feedback of CIA and
possibly in the pathogenesis of rheumatoid arthritis.
Introduction
Locally produced proinflammatory cytokines such as tumor
necrosis factor-α, interleukin (IL)-1, and IL-6 play a pivotal role
in the pathology of rheumatoid arthritis (RA). These cytokines,
by upregulation of several genes, are responsible both for the
recruitment and continuous activation of the inflammatory cells
and for inducing production of the enzymes that destroy bone
and cartilage. However, these inflammatory events need to be
balanced by the production of endogenous inhibitors, as
inflammatory responses are generally localized and the conse-
quent destruction of affected joints is less severe [1].
The ubiquitously expressed heme enzyme indoleamine 2,3-
dioxygenase (IDO) catalyzes the non-hepatic oxidative degra-
dation of tryptophan, the initial and rate-limiting step in tryp-
tophan metabolism, resulting in depletion of this least
abundant essential amino acid. Tryptophan starvation enables
the host to restrict the growth of intracellular pathogens [2].
The expression of IDO in healthy tissues is generally quite low
but is markedly upregulated in response to infection and
inflammation. Recent studies have established an entirely
novel important biological function for IDO. These studies indi-
cate that IDO-mediated tryptophan depletion in vitro results in
inhibition of matrix-degrading metalloproteinase enzyme pro-
duction, suppression of inflammatory responses, and
1-MT = 1-methyl-tryptophan; CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; CII = type II collagen; CTLA-4 = cytotoxic T lym-
phocyte-associated antigen-4; ELISA = enzyme-linked immunosorbent assay; IDO = indoleamine 2,3-dioxygenase; IFN-γ = interferon-γ; IgGAM = 
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promotion of immune tolerance [3,4]. Accordingly, an emerg-
ing immunological paradigm regards IDO as a key regulatory
control enzyme in both innate and adaptive immune
responses. Indeed, modulation of cellular IDO expression and/
or activity is now increasingly implicated in inflammation and
autoimmunity, organ transplantation and fetal rejection, and
evasion of immune surveillance by tumor cells. Furthermore,
agents that inhibit IDO are under active investigation as poten-
tial adjuvants for tumor immunotherapy [5].
IDO-mediated tryptophan catabolism results in depletion of
tryptophan with concomitant generation of kynurenine and ulti-
mately NAD (nicotinamide adenine dinucleotide). Expression
of the IDO gene is induced in most cell types in response to
infection with microbial agents via activation of toll-like recep-
tors. Furthermore, interferon-gamma (IFN-γ), IL-10, and cyto-
toxic T lymphocyte-associated antigen-4 (CTLA-4) have also
been shown to stimulate IDO [4,6]. In contrast, IL-4, IL-13, and
transforming growth factor-β are suppressors of IDO [7]. In
previous studies, we have shown that IFN-γ caused time-
dependent induction of IDO gene expression and activity in
cultured normal fibroblasts [4]. The consequent tryptophan
catabolism and ensuing tryptophan starvation in these cultures
were associated with profound suppression of collagenase
and stromelysin gene expression induced by IL-1β. Abrogation
of IL-1β-induced matrix metalloproteinase stimulation upon
activation of IDO in these fibroblasts was directly due to the
reduction of local tryptophan concentrations rather than the
accumulation of kynurenine and other tryptophan metabolites.
These observations led us to propose the hypothesis that,
through its ability to induce transient tryptophan starvation,
IDO represented an important endogenous anti-inflammatory
mechanism and that disruption of IDO induction or function
would be associated with exaggerated inflammatory
responses.
Collagen-induced arthritis (CIA) is generated in genetically
susceptible mouse or rat strains by immunization with type II
collagen (CII) dissolved in complete Freund's adjuvant (CFA).
CIA highly resembles RA according to overlapping immun-
opathogenic pathways and similar histopathologic features
[8]. Among other reasons, the central role of class II major his-
tocompatibility complex [9], the involvement of CD4+ T cells in
the immunopathogenesis of the disease, the predominantly
Th1 type immune response to CII in the induction phase
[10,11], as well as the cytokine profile throughout the evolu-
tion of CIA [12] make this experimental animal model one of
the most adequate models of RA. To address the question of
whether IDO plays a negative regulatory role in an animal
model of arthritis, we assessed IDO activity in the sera of mice
at different stages of arthritis and the effect of 1-methyl-tryp-
tophan (1-MT), a specific inhibitor of IDO, on arthritis develop-
ment and antigen-specific immune responses in CIA.
Materials and methods
Immunization and assessment of collagen-induced 
arthritis in mice receiving either 1-methyl-tryptophan or 
vehicle
Mice were housed and bred under standard conditions at the
Comparative Research Center of Rush University (Chicago,
IL, USA). The Institutional Animal Care and Use Committee
approved all animal experiments. DBA/1 male mice, 6 to 8
weeks of age, were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA). Mice were immunized by a standard
immunization protocol. Briefly, 100 μg of human CII was emul-
sified in CFA (Difco Laboratories Inc., now part of Becton
Dickinson and Company, Franklin Lakes, NJ, USA) and
injected into the proximal tail of mice. A second injection of the
same dose and adjuvant was given intraperitoneally (i.p.) on
day 21. Mice that did not develop arthritis within 3 weeks of
the second antigen injection were boosted with a third injec-
tion administered in equally divided doses i.p. and into the
proximal tail. All mice were sacrificed 8 weeks after the first
injection. After the second immunization, all mice were exam-
ined for swelling and erythema of distal joints. Paws were con-
sidered to have arthritis when swelling and erythema were
noted in at least two digits and/or other joints. The clinical
severity of arthritis was graded on a scale of 0 to 4 for each
paw, according to swelling and redness. Specifically, scoring
was performed as follows: 0 = healthy; 1 = mild swelling and
erythema; 2 = moderate swelling and erythema; 3 = more
intense erythema, swelling, and redness affecting a greater
proportion of the paw; 4 = severe erythema, swelling, and red-
ness affecting the entire paw. A cumulative score ranging from
0 to 16, based on individual paw scores of 0 to 4, was
assigned for each animal.
Tablets containing slow release of D, L-1-MT (Innovative
Research of America, Sarasota, FL, USA) or vehicle were sur-
gically inserted under the dorsal skin of mice on days 22 and
29 after the first immunization. The tablets released 10 mg/day
1-MT for a period of 7 to 10 days.
Measurement of antibody production and T-cell 
response
Antibodies to the immunizing human and mouse (self) carti-
lage CII were determined by enzyme-linked immunosorbent
assay (ELISA), as described elsewhere [13-15]. Briefly, Max-
isorp 96-well plates (Nalge Nunc, Naperville, IL, USA) were
coated with 0.1 μg of human or mouse cartilage-derived CII in
100 μl of coating buffer. Antibodies were determined in serial
dilutions of sera (1:500 to 1:62,500) using peroxidase-conju-
gated goat anti-mouse immunoglobulins G, A, and M (IgGAM)
secondary antibodies (Zymed Laboratories Inc., now part of
Invitrogen Corporation, Carlsbad, CA, USA). Serum antibody
levels were expressed in milligrams per liter using mouse
IgGAM as control (Invitrogen Corporation).Available online http://arthritis-research.com/content/9/3/R50
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Antigen-specific T-cell responses, including IL-2 production
and T-cell proliferation, were measured in quadruplicate sam-
ples of spleen cells (3 × 105 cells per well) cultured in the
presence of 100 μg of collagen protein per milliliter. IL-2 was
measured in supernatants harvested on day 2 by the prolifera-
tion of the IL-2-dependent CTLL-2 cell line. Antigen-specific T-
cell proliferation was assessed on day 5 by the incorporation
of 3 [H]thymidine. In both cases, the antigen-specific response
was expressed as stimulation index, which is a ratio of incor-
porated 3 [H]thymidine (counts per minute) in silver-stimulated
cultures relative to counts per minute in non-stimulated cul-
tures [13,14]. Antigen-specific IFN-γ and IL-4 production by T
cells was determined in culture conditions identical to those
described for T-cell proliferation in 4-day-old conditioned
medium (2.5 × 106 mononuclear cells per milliliter) using cap-
ture ELISAs (R&D Systems, Inc., Minneapolis, MN, USA).
High-performance liquid chromatography analysis
Serum tryptophan (T) and kynurenine (K) concentrations were
measured simultaneously by high-performance liquid chroma-
tography, as previously described [16]. As relatively high vol-
umes of sera are needed for the determination of K and T,
pooled sera were used, K and T concentrations were deter-
mined, and then K/T ratios were calculated.
Statistical analysis
Analyses of the arthritis score and disease incidence at differ-
ent time points were carried out using the non-parametric
Mann-Whitney U  test and chi-square contingency analysis,
respectively. Student t test was used for statistical analysis of
all other data. Analyses were performed using SPSS version
7.5 software package (SPSS Inc., Chicago, IL, USA). Signifi-
cance was set at a p value of less than 0.05.
Results
Clinical and histological features of arthritis: increase of 
both the incidence and severity in mice treated with 1-
methyl-tryptophan
Mice were immunized with CII and monitored for the develop-
ment of arthritis for 54 days after the primary immunization.
Clinical signs of arthritis typically appeared within 4 to 8 days
after the second and third injections, which were administered
on days 21 and 42 after the primary immunization, respec-
tively. Treatment with 1-MT administered by the insertion of
tablets containing 1-MT (or vehicle) on days 22 and 29 after
the first injection resulted in an increased incidence of arthritis
(Figure 1a). In addition to the higher disease incidence, the
severity indicated by the cumulative arthritis score was signifi-
cantly increased in mice receiving 1-MT as compared to those
receiving vehicle between days 37 and 47 after the primary
immunization (Figures 1b and 2). Histological analysis of the
ankle, metatarsophalangeal, and interphalangeal joints of 1-
MT-treated and vehicle-treated mice showed typical arthritis
characterized by extensive leukocyte infiltration, synovial prolif-
eration, pannus formation, and erosions. The severity of inflam-
matory cell infiltration and destruction of cartilage and bone
reflected the clinical state, but no qualitative differences could
be observed in mice receiving 1-MT compared to control mice.
Cellular and humoral immune responses
Because of the differences in incidence and severity of arthritis
between mice receiving 1-MT or vehicle, it seemed to be pru-
dent to detect immune responses to CII. Significant increases
were found in both CII-specific autoantibody and heteroanti-
body titers in 1-MT-treated mice compared to the vehicle
group; however, these differences disappeared by the end of
the follow-up period (day 55) (Figure 3a,b). When assessing
T-cell proliferation in the two groups at the end of follow-up, no
Figure 1
Incidence and severity of collagen-induced arthritis (CIA) in mice  treated with 1-methyl-tryptophan (1-MT) or vehicle Incidence and severity of collagen-induced arthritis (CIA) in mice 
treated with 1-methyl-tryptophan (1-MT) or vehicle. Arthritis was first 
detected on day 26 after immunization with type II collagen on days 0, 
21, and 42 (solid arrows) in mice treated with 1-MT or vehicle (open 
arrows). (a) Incidence of CIA expressed as the percentage of arthritic 
animals. (b) Disease severity expressed as the cumulative arthritis 
score in affected animals. Statistically significant differences in arthritis 
scores were found between days 37 and 47 (p < 0.05). Values are pre-
sented as the mean and standard error of the mean of 25 1-MT-treated 
and 20 vehicle-treated DBA/1 mice per group and represent two inde-
pendent experiments.Arthritis Research & Therapy    Vol 9 No 3    Szántó et al.
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differences in T-cell responses to heterologous CII, and only
moderately increased T-cell proliferation to autologous CII in
the 1-MT group, could be detected. Similarly to T-cell prolifer-
ation, IL-2 concentrations in the supernatants of spleen cells
stimulated with mouse or human CII were slightly (but non-sig-
nificantly) higher in the 1-MT-treated group than in vehicle-
treated group at the end of the follow-up (data not shown).
Spleen cell supernatant cytokine levels in mice with 
collagen-induced arthritis treated with 1-methyl-
tryptophan or vehicle
The concentrations of IFN-γ and IL-4 were determined in the
supernatants of spleen cells from mice with CIA and treated
with 1-MT or vehicle, respectively, at the end of the follow-up.
Cytokine production of cells was assessed either without stim-
ulation or after challenging with mouse or human CII. A lower
concentration of IL-4 was detected in supernatants of spleen
cells from mice treated with 1-MT in comparison to treated
those with vehicle, but the difference was significant only
when challenging the cells with human CII (p < 0.05) (Figure
4a). In contrast, slightly (but non-significantly) higher concen-
trations of IFN-γ could be measured in supernatants of spleen
cells from 1-MT-treated mice compared to those from vehicle-
treated animals (Figure 4b).
Kynurenine/tryptophan ratios in collagen-induced 
arthritis mice treated with 1-methyl-tryptophan or 
vehicle
To estimate the enzymatic activity of IDO in different stages of
arthritis, K and T concentrations were measured and K/T ratios
were calculated in the pooled sera of mice treated with 1-MT
or vehicle. Increased K and decreased T concentrations were
measured, and thus increased K/T ratio was detected in mice
with acute arthritis, but this ratio was even higher in immunized
and immediate pre-arthritic mice (day 33). Thus, on day 33,
animals that will not subsequently develop arthritis have higher
K/T ratios in comparison to those that will develop arthritis. As
was expected, treatment with 1-MT decreased the K/T ratio in
the serum of arthritic and immediate pre-arthritic mice com-
pared to the vehicle-treated ones. At the end of follow-up, the
K/T ratio of mice was as low as that of the immunized mice. 1-
MT treatment did not have any effect on K/T ratio (Figure 5).
Discussion
RA and experimental inflammatory joint diseases have a pro-
gressive character with involvement of increasing numbers of
joints; however, the initial and aggressive acute phase in
affected joints slows down over time and the inflammatory
processes burn out. Several lines of evidence indicate that the
effector mechanism that initially attacks the joints is T cell-
driven in response to the effect of proinflammatory cytokines,
but the mechanisms responsible for the limitation of acute
inflammatory processes are much less understood. The novel
finding of our study is that IDO activity is upregulated in the
acute phase of CIA reflected by the increased K/T ratio in the
serum. Furthermore, we could also demonstrate that inhibition
of IDO in this experimental model augments the incidence and
severity of the disease and increases the immune responses
to the autoantigens and alloantigens. These data suggest that
IDO plays a central role in the negative regulatory feedback of
immunological mechanisms in inflammatory joint diseases.
CIA, like RA in humans, is characterized by the accumulation
of T cells, plasma cells, macrophages, B cells, mast cells, nat-
ural killer (NK) cells, and dendritic cells in the synovial sublin-
ing [17,18]. Furthermore, inflammatory cells infiltrating the
synovial tissue in RA and in the acute phase of CIA exhibit a
predominantly Th1 pattern of cytokine expression [10,11]. By
priming the Th1-type inflammatory cell responses, IFN-γ is one
of the most important proinflammatory factors in the induction
of T cell-driven autoimmune arthritis, such as CIA. However,
IFN-γ plays an ambiguous role in autoimmunity. After the acti-
vation of self-reactive lymphocyte clones and of bystander and
accessory cells in the acute phase, IFN-γ downregulates the
autoimmune processes [19]. Indeed, CIA and CFA developed
more readily in IFN-γ receptor-deficient mice than in wild-type
Figure 2
Hind paw images of DBA mice Hind paw images of DBA mice. (a) Hind paws of healthy non-immunized DBA mice. (b) Type II collagen-immunized (arthritic) DBA mice treated with 
1-methyl-tryptophan 6 to 7 days after the onset of collagen-induced arthritis. (c) Type II collagen-immunized (arthritic) DBA mice treated with vehicle 
6 to 7 days after the onset of collagen-induced arthritis. According to our scoring system (see Materials and methods), the three stages have been 
assigned scores of 0 (a), 4 (b), and 3 (c).Available online http://arthritis-research.com/content/9/3/R50
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littermates [20]. As a possible explanation, it has emerged that
CFA elicits strong myelopoiesis and expansion of Mac-1+
cells, which play a crucial role in disease pathogenesis, and
this process is downregulated by IFN-γ [20]. However, the
exact mechanism responsible for the effect of IFN-γ in CIA has
not been fully elucidated.
One of the most likely mechanisms for the downregulation of
CIA by IFN-γ is the increased expression of IDO by non-T cells
[21]. In fibroblasts [22], macrophages [23], and dendritic cells
[3], IFN-γ stimulates the enzyme IDO, which degrades the
amino acid tryptophan to form kynurenine, resulting in the inhi-
bition of autoimmune processes. According to this assump-
tion, we demonstrated an elevated K/T ratio, indicating high
IDO activity during the acute phase of CIA. Moreover, the K/T
ratio was even higher in mice that received CII and CFA but
developed no clinical and histological signs of arthritis. These
data suggest that IDO acts as a negative feedback in this
model, and the onset and severity of experimental arthritis are
inversely proportional to IDO activity.
To confirm the regulatory role of IDO in CIA, we used 1-MT, a
known competitive inhibitor of IDO. 1-MT did not influence
IFN-γ, but it significantly suppressed IL-4 production by spleen
cells, resulting in an increased Th1/Th2 response. In 1-MT-
treated mice, we could demonstrate a significant decrease of
K/T ratio in the immediate pre-arthritic and acute phase of
arthritis compared to vehicle-treated animals, suggesting the
high activity of IDO only in these stages of inflammatory proc-
esses. In other words, the low blocking activity of 1-MT either
in the pre-arthritic phase or in the chronic phase of arthritis
denotes the anti-inflammatory effect of IDO only in the case of
Figure 3
Humoral immune responses in DBA mice immunized with type II colla- gen (CII) and complete Freund's adjuvant (CFA) and treated with 1- methyl-tryptophan (1-MT) or vehicle Humoral immune responses in DBA mice immunized with type II colla-
gen (CII) and complete Freund's adjuvant (CFA) and treated with 1-
methyl-tryptophan (1-MT) or vehicle. (a) Concentrations of antibodies 
(total concentrations of IgGAM [immunoglobulins G, A, and M]) to het-
erologous (human) CII were determined in the serum of DBA/1 mice 
immunized with CII and CFA and treated with 1-MT or vehicle. (b) Con-
centrations of antibodies (total concentrations of IgGAM) to autologous 
(mouse) CII were determined in the serum of DBA/1 mice immunized 
with CII and CFA and treated with 1-MT or vehicle. Sera were obtained 
on days 5, 22, 33, and 54. Values are presented as the mean and 
standard error of the mean of 25 1-MT-treated and 20 vehicle-treated 
DBA/1 mice per group and represent two independent experiments. *p 
< 0.05 between vehicle and 1-MT-treated mice on the corresponding 
days.
Figure 4
Concentrations of interleukin-4 (IL-4) and interferon-γ (IFN-γ) in the  supernatants of spleen cells harvested from mice with collagen- induced arthritis and treated with 1-methyl-tryptophan (1-MT) or vehicle Concentrations of interleukin-4 (IL-4) and interferon-γ (IFN-γ) in the 
supernatants of spleen cells harvested from mice with collagen-
induced arthritis and treated with 1-methyl-tryptophan (1-MT) or vehi-
cle. The release of IL-4 (a) and IFN-γ (b) into the supernatants of spleen 
cells in response to human or mouse type II collagen (CII) was deter-
mined at the end of the experiment. Values are presented as the mean 
and standard error of the mean of 16 animals per group (*p < 0.01).Arthritis Research & Therapy    Vol 9 No 3    Szántó et al.
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upregulation of inflammatory processes, especially Th1
responses.
As a tryptophan-catabolizing enzyme, IDO can induce the
peripheral tolerance and reduce the persistent immune activa-
tion. On one hand, IDO decreases the tryptophan concentra-
tion in the microenvironment of inflammatory cells. Although
tryptophan is an essential amino acid indispensable for the
biosynthesis of proteins, the low tryptophan concentration
results in the arrest of cell proliferation in the mid-G1 arrest
point. T cells are specifically sensitive to tryptophan depriva-
tion [2,5] and thus IDO activity can block the potential harmful
autoimmune response. On the other hand, Zhu and colleagues
[24] proposed that synovial T cells derived from RA synovial
fluids are resistant to IDO-mediated tryptophan deprivation.
This may be one mechanism by which autoreactive T cells are
sustained in vivo in patients with arthritis [24]. In addition,
selected metabolites on the tryptophan-kynurenine pathway
are able to suppress proliferation of allogeneic T cells and, to
a lesser extent, B and NK cells [25]. Moreover, some of the
kynurenine derivates can induce in vitro the selective apopto-
sis of Th1 cells, but not Th2 cells [7]. In accordance with these
results, 1-MT treatment in our study resulted in an increased,
mainly Th1 cell-mediated immune response to the CII and con-
sequently in the significant worsening of severity and increase
of onset of CIA mediated by Th1 response.
In this regard, recent studies with the CIA model of arthritis
using an antibody to the costimulatory molecule CD137, a
member of the tumor necrosis factor receptor superfamily, are
of great interest. These results showed that treatment of mice
with the anti-CD137 antibody resulted in induction of IDO in
vivo, which was associated with significant amelioration of the
severity of CIA [26]. Furthermore, pharmacological inhibition
of IDO reversed the effects of the anti-CD137 antibody and
aggravated the arthritis in this model.
The tryptophan-IDO pathway may have important relevance
for the biological therapy of RA. In a study of Boasso and col-
leagues [27], CTLA-4-Fc treatment of human peripheral blood
CD4+ T cells resulted in increased IDO expression by these
cells. This effect was not observed in CD8+ T cells. Thus,
abatacept (CTLA4-Ig) therapy may act, at least in part, by the
stimulation of IDO production.
Conclusion
The importance of IDO activity in the regulation of CIA sup-
ports the hypothesis that IDO expression by antigen-present-
ing cells is responsible for suppression of undesirable Th1
cells in human inflammatory joint diseases, as tryptophan deg-
radation could be demonstrated in patients with RA [28].
These findings theoretically raise the possibility that the local
or systematic induction of IDO activity could be tested in
inflammatory joint diseases.
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